Literature DB >> 1760861

Combined haemoperfusion, haemofiltration and haemodialysis for systemic detoxification in locoregional 5-fluorouracil therapy.

F Keller1, U Gallkowski, W Roth, J Boese-Landgraf.   

Abstract

Combined haemoperfusion, haemofiltration and haemodialysis (HPFD) was examined for its systemic effect on 5-fluorouracil (5-FU) kinetics after locoregional application to one female patient with liver metastases of a colon carcinoma. During each HPFD treatment, which lasted 4 h, 5-FU was given via a port-a-cath system into the hepatic artery on 4 separate days. The HPFD extraction rate was 99%. Extracorporal 5-FU clearance (89 ml/min) was 9% of total body clearance (1094 ml/min). The fraction eliminated within 4 h was only 6% of the applied dose (3500-4000 mg 5-FU). Sufficient extracorporal detoxification during combined HPFD can thus not be guaranteed in locoregional chemotherapy with a high dose of 5-FU.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1760861     DOI: 10.1007/bf00687329

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  9 in total

1.  Superiority of selective bolus infusion and simultaneous rapid removal of anticancer agents by charcoal hemoperfusion in cancer treatment.

Authors:  T Kihara; H Nakazawa; T Agishi; H Honda; K Ota
Journal:  ASAIO Trans       Date:  1988 Jul-Sep

2.  Time-dose relationships for 5-fluorouracil cytotoxicity against human epithelial cancer cells in vitro.

Authors:  P M Calabro-Jones; J E Byfield; J F Ward; T R Sharp
Journal:  Cancer Res       Date:  1982-11       Impact factor: 12.701

Review 3.  Metabolism and mechanism of action of 5-fluorouracil.

Authors:  W B Parker; Y C Cheng
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

4.  Removal of methotrexate, leucovorin, and their metabolites by combined hemodialysis and hemoperfusion.

Authors:  M V Relling; F B Stapleton; J Ochs; D P Jones; W Meyer; I W Wainer; W R Crom; C P McKay; W E Evans
Journal:  Cancer       Date:  1988-09-01       Impact factor: 6.860

Review 5.  5-Fluorouracil-associated cardiotoxicity.

Authors:  N J Freeman; M E Costanza
Journal:  Cancer       Date:  1988-01-01       Impact factor: 6.860

6.  Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients.

Authors:  J G Wagner; J W Gyves; P L Stetson; S C Walker-Andrews; I S Wollner; M K Cochran; W D Ensminger
Journal:  Cancer Res       Date:  1986-03       Impact factor: 12.701

7.  [Regional chemotherapy of liver metastases in colorectal carcinoma. Intra-arterial vs intravenous plus intra-arterial therapy].

Authors:  F Safi; R Roscher; R Bitter; K A Schumacher; W Gaus; H G Beger
Journal:  Dtsch Med Wochenschr       Date:  1989-09-29       Impact factor: 0.628

8.  Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastases.

Authors:  J A Goldberg; D J Kerr; N Willmott; J H McKillop; C S McArdle
Journal:  Br J Cancer       Date:  1988-02       Impact factor: 7.640

9.  Continuous 5-day regional chemotherapy by 5-fluorouracil in colon carcinoma: pharmacokinetic evaluation.

Authors:  J L Boublil; G Milano; R Khater; J Bourry; A Thyss; J N Bruneton; N Renée; C Philip; M Namer
Journal:  Br J Cancer       Date:  1985-07       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.